Azarest 300MG (Azacitidine)
Product Name : Ibrutix (Ibrutinib)
Generic Name : Ibrutinib INN
Formulation : Capsule
Available Pack Size : 120’s in a bottle
Available Strengths : 140 mg
Registrations : Bangladesh
Product Information
Azarest (Azacitidine) 300mg is an oral pyrimidine nucleoside metabolic inhibitor (hypomethylating agent) used for continued treatment of adults with Acute Myeloid Leukaemia (AML) who achieved remission after induction chemotherapy, and, per regional labelling, in the management of myelodysplastic syndromes (MDS) and chronic myelomonocytic leukaemia (CMML). It works by inhibiting DNA methyltransferase after being incorporated into DNA and RNA, reducing abnormal DNA methylation and reactivating genes involved in normal blood cell differentiation and tumour suppression. Azarest is the oral tablet formulation and is not interchangeable with injectable (subcutaneous or intravenous) azacitidine, which has different absorption and dosing. Manufactured by Everest Pharmaceuticals Ltd., Bangladesh and globally supplied by Mediaid Pharmacy with worldwide shipping.
Basic Product Information of Azarest (Azacitidine) 300mg
| Brand Name | Azarest (Azacitidine) |
| Generic Name | Azacitidine INN |
| Drug Class | Pyrimidine Nucleoside Metabolic Inhibitor (Hypomethylating Agent) |
| Available Strength | 300mg |
| Formulation | Film-Coated Tablet (Oral – Not Interchangeable with Injectable Azacitidine) |
| Pack Size | 14 Tablets per Pack |
| Primary Indication | Continued (Maintenance) Treatment of Acute Myeloid Leukaemia in Remission |
| Regulatory Approvals | USFDA Approved (Oral Azacitidine, AML Maintenance). Also registered regionally for MDS and CMML. |
| Originator Brand | Onureg (oral) by Bristol Myers Squibb; Vidaza (injectable) by Bristol Myers Squibb |
| Manufacturer | Everest Pharmaceuticals Ltd., Dhaka, Bangladesh |
| Global Supplier | Mediaid Pharmacy, Worldwide Shipping Available |
| Registration | Registered in Bangladesh |
| Storage Conditions | Store below 30 degrees Celsius. Keep in a dry place away from light and moisture. Keep out of the reach of children. |
How Azarest (Azacitidine) Works
Azarest contains Azacitidine, a pyrimidine nucleoside analogue of cytidine. Following cellular uptake, Azacitidine is enzymatically converted into nucleotide triphosphates and incorporated directly into both DNA and RNA. Once incorporated into DNA, Azacitidine inhibits DNA methyltransferase, the enzyme responsible for adding methyl groups to DNA.
In myeloid malignancies, abnormal hypermethylation can silence genes that would otherwise regulate normal cell differentiation and tumour suppression. By reducing this abnormal DNA methylation, Azarest helps reactivate silenced genes, restoring more normal patterns of gene expression, promoting differentiation of abnormal bone marrow precursor cells, and inducing apoptosis (programmed cell death) in malignant cells.
Azarest is taken as an oral tablet. Because oral Azacitidine has different absorption characteristics than the injectable form, its dosing schedule and approved use are specific to the oral formulation and should not be assumed to match injectable azacitidine regimens.
Indications for Azarest (Azacitidine)
Azarest (Azacitidine) is indicated for the following conditions:
|
Continued Treatment of Acute Myeloid Leukaemia (AML) For continued (maintenance) treatment of adult patients with AML who achieved complete remission, or complete remission with incomplete blood count recovery, following intensive induction chemotherapy, and who are unable to complete intensive curative therapy. |
|
Myelodysplastic Syndromes (MDS) and CMML Azarest is also registered regionally for the management of myelodysplastic syndrome subtypes (including refractory anaemia, refractory anaemia with ringed sideroblasts, refractory anaemia with excess blasts, and refractory anaemia with excess blasts in transformation) and chronic myelomonocytic leukaemia (CMML), consistent with the traditional indications of azacitidine as a class. The prescribing oncologist should confirm the appropriate dosing schedule for these indications, as it may differ from the AML maintenance regimen described below. |
Benefits of Azarest (Azacitidine) 300mg
|
Oral Alternative to Injections Azarest offers an oral tablet option where azacitidine has traditionally been given by subcutaneous or intravenous injection, reducing the burden of repeated injections for eligible patients. |
Extends Remission in AML As maintenance therapy, oral azacitidine has been shown to significantly prolong overall survival and relapse-free survival in AML patients in remission who cannot complete intensive curative treatment. |
Established Hypomethylating Mechanism Azacitidine has a long-established role in myeloid malignancy treatment, with a well-characterised mechanism and safety profile built on decades of clinical use. |
|
Affordable Alternative to Onureg/Vidaza Azarest contains the same active ingredient as Onureg and Vidaza, at a significantly lower cost, making ongoing hypomethylating therapy more financially accessible. |
Outpatient-Friendly Maintenance As an oral tablet taken at home, Azarest supports long-term AML maintenance therapy without requiring frequent clinic visits for injections. |
cGMP Certified Manufacturing Produced by Everest Pharmaceuticals Ltd. under cGMP-compliant manufacturing standards, helping ensure consistent quality, purity, and potency in every batch of Azarest tablets. |
How to Take Azarest (Azacitidine)
Route: Oral, with or without food, at approximately the same time each day. Tablets should be swallowed whole.
Standard dose for AML maintenance: 300mg (one tablet) once daily on Days 1 through 14 of each 28-day cycle, continued as long as the patient continues to benefit, exactly as directed by the prescribing haemato-oncologist.
Dosing for MDS/CMML: Where prescribed for MDS or CMML under regional labelling, the dose, schedule, and cycle length may differ from the AML maintenance regimen above; follow your prescribing physician’s specific instructions.
Missed or vomited dose: If a dose is missed or vomited, do not take an extra dose; resume the normal dosing schedule with the next planned dose, and contact your oncology team for guidance.
Formulation note: Azarest oral tablets are not interchangeable with injectable (subcutaneous or intravenous) azacitidine on a milligram-for-milligram basis, due to differences in bioavailability. Do not substitute between formulations without your oncologist’s specific guidance.
Paediatric use: The safety and efficacy of Azarest in paediatric patients have not been established. No data are currently available.
Monitoring and Dosage Adjustments
Regular monitoring is essential throughout Azarest treatment. Your oncology team will monitor complete blood counts before each treatment cycle and as clinically indicated, given the risk of myelosuppression, and will assess liver and renal function periodically. Dose interruption, reduction, or delay of the next cycle may be required based on blood count recovery. Report any fever, unusual bruising or bleeding, persistent fatigue, signs of infection, or severe nausea, vomiting, or diarrhoea to your oncology team immediately.
Drug Interactions and Important Information
Use with caution alongside other myelosuppressive medications, as combined use may increase the risk and severity of low blood counts. Inform your physician of any history of significant hepatic or renal impairment before starting treatment, as these may require closer monitoring.
Azarest can cause foetal harm and is not recommended during pregnancy; women of childbearing potential should use effective contraception during treatment and for a period after the final dose, and men should also use effective contraception during treatment and for a period afterwards, as advised by their physician. Breastfeeding is not recommended during treatment. Always inform your physician of all medications, supplements, and herbal products you are currently taking before starting Azarest.
Side Effects and Precautions
|
Common Side Effects Nausea and vomiting Diarrhoea or constipation Fatigue and dizziness Muscle and joint pain Decreased appetite Low blood counts (anaemia, neutropenia, thrombocytopenia) |
Serious Warnings and Precautions Severe myelosuppression, requiring regular blood count monitoring and possible dose interruption. Increased risk of serious infection due to low white blood cell counts. Hepatotoxicity and renal impairment, particularly in patients with pre-existing organ dysfunction. Embryo-foetal toxicity. Not recommended during pregnancy or breastfeeding. |
Who Should Use Azarest (Azacitidine)?
Azarest is suitable for adult patients with Acute Myeloid Leukaemia who have achieved remission following induction chemotherapy but are unable to complete intensive curative therapy, and, under regional labelling, for adult patients with certain myelodysplastic syndrome subtypes or chronic myelomonocytic leukaemia. It is prescribed by haemato-oncologists experienced in managing myeloid malignancies. A thorough medical assessment including baseline blood counts, liver and renal function is required before initiating treatment.
Manufacturer: Everest Pharmaceuticals Ltd.
Everest Pharmaceuticals Ltd. is a vertically integrated pharmaceutical company based in Dhaka, Bangladesh, focused on complex, technology-driven specialty medicines across oncology, nephrology, and virology. Operating under Bangladesh’s TRIPS/Doha Declaration exemption for least-developed countries, Everest manufactures advanced generics such as Azarest under cGMP-compliant standards, with the stated mission of making high-cost, life-saving medicines accessible and affordable to patients around the world. Azarest is one of Everest’s specialty haemato-oncology products, offering a bioequivalent oral alternative to Onureg and Vidaza at a fraction of the cost.
Global Supplier: Mediaid Pharmacy with Worldwide Shipping
Mediaid Pharmacy is a trusted global supplier of specialty and oncology medications. We ensure Azarest (Azacitidine) is accessible to patients and healthcare providers worldwide through reliable worldwide shipping. Whether you are located in South Asia, the Middle East, Africa, Europe, or beyond, Mediaid Pharmacy provides fast and reliable delivery with full order support. Contact us directly via WhatsApp, phone, or WeChat for pricing, availability, and delivery enquiries.
Why Choose Azarest (Azacitidine) from Mediaid Pharmacy?
Azarest represents a convenient, oral alternative to injectable hypomethylating therapy for eligible patients with AML in remission. As the generic equivalent of Onureg, it delivers the same active ingredient, Azacitidine, with the same proven hypomethylating mechanism at a dramatically more affordable price. Manufactured by Everest Pharmaceuticals Ltd. under cGMP-compliant standards and distributed globally by Mediaid Pharmacy, Azarest gives patients worldwide access to essential maintenance therapy for myeloid malignancies without the financial burden of brand-name alternatives. For patients and physicians seeking a proven, affordable, and accessible Azacitidine option with worldwide delivery, Azarest from Mediaid Pharmacy is the trusted choice.
Frequently Asked Questions About Azarest (Azacitidine)
What is Azarest (Azacitidine) used for?
Azarest (Azacitidine) tablets are used for continued (maintenance) treatment of adult patients with Acute Myeloid Leukaemia who have achieved remission following induction chemotherapy but cannot complete intensive curative therapy. It is also registered regionally for certain myelodysplastic syndrome subtypes and chronic myelomonocytic leukaemia. It works by reducing abnormal DNA methylation in blood-forming cells.
How should I take Azarest (Azacitidine)?
For AML maintenance, Azarest is taken orally, once daily, with or without food, on Days 1 through 14 of each 28-day cycle. Dosing for MDS or CMML may follow a different schedule under your physician’s specific direction. Always follow your haemato-oncologist’s exact instructions.
What strength is Azarest available in?
Azarest is available in a 300mg tablet, supplied in a pack of 14 tablets. The standard AML maintenance dose is one tablet daily for 14 days of each 28-day cycle.
Is Azarest the same as Onureg or Vidaza (Azacitidine)?
Azarest is the generic equivalent of oral Azacitidine (Onureg). It contains the same active ingredient as both Onureg (oral) and Vidaza (injectable), but as an oral tablet it is not directly interchangeable with the injectable form due to differences in absorption. Azarest is manufactured by Everest Pharmaceuticals Ltd. in Bangladesh at a significantly lower cost than the brand-name products.
What are the side effects of Azarest (Azacitidine)?
Common side effects include nausea, vomiting, diarrhoea or constipation, fatigue, muscle or joint pain, and low blood counts. Serious risks include severe myelosuppression and increased risk of infection. Always consult your haemato-oncology team for a complete assessment of your individual risks and benefits before starting treatment.
Can Azarest be used with other medications?
Use caution combining Azarest with other myelosuppressive medications, as this may increase the risk of low blood counts. Always inform your physician of all medications, supplements, and herbal products you are taking before starting Azarest.
Is Azarest (Azacitidine) safe during pregnancy or breastfeeding?
No. Azarest is not recommended during pregnancy or breastfeeding, as it can cause foetal harm. Effective contraception should be used during treatment and for a period after the final dose, by both female patients and male patients, as advised by their physician. Please consult your physician before starting treatment if you are pregnant, planning to become pregnant, or breastfeeding.
Can I order Azarest (Azacitidine) online with worldwide shipping?
Yes. Mediaid Pharmacy supplies Azarest (Azacitidine) 300mg globally with worldwide shipping. Contact us via WhatsApp, phone, or WeChat at +8801773428128 or email us at info@mediaidpharmacy.com to enquire about pricing, availability, and delivery to your country.
Order Azarest (Azacitidine) 300mg with Worldwide Shipping
Phone / WhatsApp / WeChat: +8801773428128 | Email: info@mediaidpharmacy.com
